ATROMID-S Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atromid-s, and when can generic versions of Atromid-s launch?
Atromid-s is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in ATROMID-S is clofibrate. There are four drug master file entries for this compound. Additional details are available on the clofibrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATROMID-S?
- What are the global sales for ATROMID-S?
- What is Average Wholesale Price for ATROMID-S?
Summary for ATROMID-S
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 132 |
| Patent Applications: | 3,946 |
| DailyMed Link: | ATROMID-S at DailyMed |
US Patents and Regulatory Information for ATROMID-S
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | ATROMID-S | clofibrate | CAPSULE;ORAL | 016099-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
